NEW YORK – Norwegian cardiovascular diagnostic firm CardiNor announced on Monday that its cardiovascular risk disease test has received CE marking.
The CardiNor Secretoneurin ELISA test measures secretoneurin, a novel biomarker that is "an independent and strong predictor of mortality" in patients with cardiovascular disease, including ventricular arrhythmia and acute heart failure, as well as patients with acute respiratory failure who have severe sepsis, the firm said in a statement.
The test is currently being trialed in patient selection for cardiac rhythm management using implantable cardiac defibrillator devices, Oslo-based CardiNor said, adding it is intended to provide clinicians with a tool for risk prediction and patient management.
CardiNor is "now looking forward to expanding our distribution network globally and to prepare for US market entry," company CEO Dag Christiansen said in a statement.
In April 2021, the firm raised NOK 12 million ($1.4 million) to develop the test.